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 Introduction 
The last few years have VHHQWKHGHYHORSPHQWRIVHYHUDO³YDOXHIUDPHZRUNV´IRUDVVHVVLQJWKH 
relative merits and prices of FDQFHUGUXJVLQFOXGLQJ$6&2¶VRZQYDOXHIUDPHZRUN (Schnipper 
et al, 2016). These frameworks can have many different aims and audiences (Neumann and 
Cohen, 2015; Mandelblatt et al, 2017).  For example they may be designed to support social 
decisions about value, as in the case of DrugAbacus1. $6&2¶V IUDPHZRUN LV GHVLJQHG to 
support individual clinical decisions through comparative assessment of treatment alternatives, 
contemplated as part of the dialogue between patient and physician.   
 
In this paper we inquire as to whether the ASCO framework can be considered as a valid system 
for measuring patient value, and thus for supporting decisions.  We contrast it with some tools 
which have been developed by those within and affiliated with the Medical Decision Making 
community, with a view to making constructive suggestions for the ongoing development of 
the framework.  
 
The ASCO framework as a tool for measuring value 
 
Value frameworks should produce a score which measures value in a similar way to the way 
in which a thermometer measures temperature.  In the ASCO approach, as the thermometer 
converts the true temperature to a temperature reading, the ASCO framework converts the 
hazard ratio IURPDFRPSDUDWLYHFOLQLFDOWULDOWRDQHVWLPDWHRIDWUHDWPHQW¶VYDOXHBut using 
the hazard ratio for this purpose poses a challenge, as the ratio says little nothing about baseline 
risk, and therefore nothing about the magnitude of the potential benefit.   
                                                     
1 https://drugpricinglab.org/tools/drug-abacus/2 https://www.cdc.gov/nchs/data/nvsr/nvsr65/nvsr65_04.pdf 
 Consider the impact of moving from Texas to New York State, focusing on the change in the 
risk of death from car accidents and lightning strikes.  The annual mortality risk from car 
accidents falls from 13.8 to 5.5 per 100 thousand2, the annual mortality risk from lightning 
strikes is about 7.1 per 100 million in Texas and 2 per 100 million in New York3.  If one 
compares the risk reduction, which is analogous to the hazard ratio, the reduction in the risk of 
lightning strikes is nearly 4/10, the risk reduction in car accidents closer to 3/10.  This ASCO 
framework gives 70 points for the lightning benefit, only 60 for the car fatality benefit, slightly 
favouring the former, even though from a lives saved perspective the car fatality benefit is 1000 
times as large.  In other words, the framework produces precisely the reverse of what one would 
intuitively consider to be more valuable.  While this may seem a made-up example, the problem 
with relying on a relative metric finds resonance in oncology examples ± absolute benefits from 
adjuvant treatment are routinely larger than those from metastatic treatment, while the reverse 
pattern is often seen in their hazard ratios.   
 
 
Another feature of the ASCO approach is that a treatment which offers no clinical benefit can 
actually perform quite well, due to the fact that toxicity is considered separately from the 
measure of clinical benefit.  For instance, an effective but toxic treatment with a hazard ratio 
of 17/20 compared would earn 15 points on the clinical benefit score.  But because having 
favourable side effects garners independent points, a piece of candy would actually garner more 
points (20), because it has no side effects, even though it has no benefits either.   
 
                                                     
2 https://www.cdc.gov/nchs/data/nvsr/nvsr65/nvsr65_04.pdf 
3 https://weather.com/storms/severe/news/lightning-deaths-by-state-2005-2014 
Our point is not that patients may have different preferences for life extension versus toxicity 
± this is recognised by Schnipper et al ± but rather that it seems wrong to assign points for non-
toxicity independent of the clinical benefit offered.  Comparing cancer treatment to candy is of 
course absurd, but the reality is that there are many treatments in oncology that have no or 
minimal evidence of clinical benefit.  If no clinical benefit is offered, then being non-toxic is 
not by itself a positive feature.  (This argument is developed more fully in Morton, 2017a.)   
 
Some readers may object that the framework is meant to be used for the analysis of cancer 
drugs, not our cartoon examples.  But it is hard to see why we should believe frameworks which 
GRQRWJLYHWKHULJKWDQVZHUWR³QR-EUDLQHU´TXHVWLRQV (would you prefer to reduce by 50% 
your mortality risk from a major cause of death like car accidents or a minor one like lightning 
strikes?; would you, as a cancer patient, prefer clinically effective medicine or clinically 
ineffective candy?) will give the right answer in situations where the answers are less obvious.   
 
Opportunities for development 
 
Health economics and clinical decision science over the last few decades have developed 
several tools for value measurement.   
 
In health economics, a core concept is the Quality-Adjusted Life Year or QALY (Drummond 
et al, 2015; Briggs et al, 2006).  This is a measure of clinical benefit which measures time alive 
adjusted for quality.  In Figure 1, for example, we can see and compare two life trajectories, C 
and T.  It can be seen that T gives longer life in better quality than C, and the degree of benefit 
can be quantified by the dark gray area of the chart between the two curves. 
 
 Figure 1.  The QALY approach to measuring clinical benefit 
 
The QALY is not without its controversies, but it does capture what people want their medical 
treatment to provide, namely longer life in better health. It explicitly incorporates treatment 
toxicity to the extent that the toxicity reduces quality of life.   In this sense we would argue that 
it is a better measure of value than the hazard ratio.   
 
A focus of life expectancy and health related quality of life presupposes that all that matters to 
the patient in making a decision is health.  But qualitative research has identified disease 
burden, alternative available treatments, quality of evidence and convenience as factors that 
are also important when considering treatments (Baba et al, 2017).  In this case, a well-
established tool that can be used to structure such considerations is Multicriteria Decision 
Analysis or MCDA (Marsh et al, 2016; Thokala et al, 2016).  The basic idea of MCDA is a 
simple and familiar one: decision makers can be helped to analyse complex, multi-attributed 
choices by comparing the options one attribute at a time, assigning scores based on each 
attribute and weighting and summing the scores.  
 
The ASCO framework seems to be headed in the direction of MCDA (in particular it is stated 
RQSWKDWWKHLQWHQWLRQLVWRGHYHORSDVRIWZDUHWRROZKLFKZLOOSHUPLW³ZHLJKWLQJE\WKH
LQGLYLGXDO SDWLHQW´  +RZHYHU Hxperience with MCDA shows that answering clearly 
expressed weighting questions in a thoughtful way requires careful upfront investment in 
defining the criteria and extensive deliberation in response to the questions themselves.  Hence 
a major focus in MCDA research has been the development theoretically and psychologically 
well-grounded ways to ask for weights, and the provision of sensitivity analysis which can 
allow users to explore their preferences (Morton and Fasolo, 2009; Morton, 2017b).   
 
 
In our view, there is real scope to develop the ASCO value framework to add more value to 
the patient-physician interaction, drawing on the insights from the health economic and 
decision science disciplines.  For example, one way to take the ASCO framework forward 
would be to replace the Clinical Benefit dimension with absolute risk reduction, years of life 
gained or even (if QoL data is available), quality-adjusted life expectancy gains.  Additional 
considerations (for example if the patient feels that it is important that there is treatment-free 
interval) could be taken into account using MCDA methods.  
 
Conclusion 
Organisations such as a ASCO have a critical role in formulating policy around cancer decision 
making.  However, tKH$6&2YDOXHIUDPHZRUNIHHOVOLNHLWKDVEHHQEXLOW³JURXQGXS´ from 
data which is available through clinical trials.  Although a natural way to proceed, we believe 
that a better and more scientific way to approach the development of such a framework is to 
focus on the decision itself: this means identifying the core construct which one wants to 
measure and building a framework which operationalizes that core concept.  This is likely to 
revolve around what patients value in terms of their cancer care and treatment, and this would 
be consistent with a patient-centric approach to assessing value. Although evaluating cancer 
drugs present distinctive challenges, researchers in health economics and the decision sciences 
have produced robust and patient-centred frameworks to guide decision making.  We believe 
that as the ASCO framework develops, there is much scope to learn from this wider body of 
research in the important search for value in cancer care. 
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